Transverse myelitis other diagnostic studies
Jump to navigation
Jump to search
|
Transverse myelitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Transverse myelitis other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Transverse myelitis other diagnostic studies |
|
Risk calculators and risk factors for Transverse myelitis other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
Overview
- There is no non-imaging, non-laboratory diagnostic study that independently confirms or excludes transverse myelitis.
- The studies below are adjunctive. They may help localize nervous-system dysfunction, evaluate a specific associated disorder, distinguish a peripheral mimic, or characterize complications such as neurogenic bladder. They do not demonstrate spinal-cord inflammation and must not be used alone to satisfy the diagnostic criteria for transverse myelitis.[1]
- These tests should be selected to answer a defined clinical question and should not delay the appropriate magnetic resonance imaging evaluation or laboratory evaluation.
Adjunctive neurophysiologic studies
| Study | When it may be considered | Interpretation and limitation |
|---|---|---|
| Somatosensory evoked potentials (SSEPs) | May be considered when objective assessment of central somatosensory-pathway conduction would help clarify localization or when an associated inflammatory demyelinating disorder is being evaluated. | An abnormal SSEP may support dysfunction along a central somatosensory pathway, but it is not specific for transverse myelitis, does not establish inflammation, and does not determine the cause. A normal SSEP does not exclude transverse myelitis. European consensus recommendations consider SSEPs potentially helpful in the differential evaluation of neuromyelitis optica spectrum disorder (NMOSD), although they are not required for that diagnosis.[2] |
| Visual evoked potentials (VEPs) | May be considered when current or previous optic neuritis, unexplained visual dysfunction, or an associated antibody-mediated demyelinating disorder is clinically suspected. | An abnormal VEP supports dysfunction of the afferent visual pathway; it does not confirm transverse myelitis. The Neuromyelitis Optica Study Group (NEMOS) recommends VEPs as a supportive differential-diagnostic study in suspected NMOSD, but they are not formally required for that diagnosis.[2] |
| Nerve conduction studies and electromyography | May be considered when the examination does not securely localize the deficit to the spinal cord, particularly when flaccid weakness, generalized areflexia, or another feature raises concern for a peripheral nerve, nerve-root, motor-neuron, neuromuscular junction, or muscle disorder. | These studies assess the peripheral neuromuscular system. An abnormal result may identify an alternative or concurrent peripheral process; it does not confirm transverse myelitis. A normal study may support, but cannot prove, central localization. Neither test forms part of the established diagnostic criteria for transverse myelitis.[1] |
Assessment of urinary dysfunction
- Urologic functional testing evaluates the consequences of spinal-cord dysfunction; it does not diagnose transverse myelitis.
- Initial evaluation of urinary symptoms should be non-invasive and risk-based. Formal invasive testing should be reserved for patients in whom the result is expected to change risk classification or management.[3][4]
| Study | Appropriate use | Interpretation and limitation |
|---|---|---|
| Bladder diary and uroflowmetry | May be used as part of the non-invasive assessment of urinary frequency, voided volume, incontinence, urinary flow, and emptying symptoms. | These studies characterize lower urinary tract function and help determine whether specialist evaluation is required. They neither confirm nor exclude transverse myelitis.[3][4] |
| Multichannel urodynamic testing | May be considered after the acute neurologic condition has stabilized when neurogenic lower urinary tract dysfunction (NLUTD) remains of uncertain risk, symptoms are persistent or worsening, complications occur, or the findings would alter management. It should not be ordered routinely solely because transverse myelitis is suspected. | Urodynamics may characterize detrusor overactivity or underactivity, impaired bladder compliance, abnormal storage pressure, or detrusor-sphincter dyssynergia. None of these findings is specific for transverse myelitis. The American Urological Association (AUA) and Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) recommend a risk-stratified approach, while the joint European Academy of Neurology, European Federation of Autonomic Societies, and International Neuro-Urology Society guideline advises against invasive urodynamics as a routine component of the initial evaluation for every neurologic patient with urinary symptoms.[3][4] |
| Cystoscopy | Has no routine role in diagnosing transverse myelitis or in the initial evaluation of uncomplicated neurogenic urinary symptoms. It may be performed for an independent urologic indication, such as unexplained hematuria, recurrent urinary tract infection, suspected urethral injury or obstruction, bladder calculi, or another structural abnormality. | Any abnormality should be interpreted as a separate urologic condition or complication and not as evidence of transverse myelitis.[3] |
Clinical interpretation
- No finding on SSEP, VEP, nerve conduction studies, electromyography, uroflowmetry, urodynamics, or cystoscopy is pathognomonic for transverse myelitis.
- Neurophysiologic studies may support localization or help identify an alternative or associated disorder; urinary studies characterize autonomic complications and guide bladder management.
- A normal result on any of these adjunctive studies does not exclude transverse myelitis.
- There are no guideline-endorsed sensitivity or specificity thresholds for using these studies to diagnose transverse myelitis.
References
- ↑ 1.0 1.1 Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002;59(4):499-505. doi:10.1212/WNL.59.4.499. PubMed identifier: 12236201.
- ↑ 2.0 2.1 Jarius S, Aktas O, Ayzenberg I, et al.; Neuromyelitis Optica Study Group. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)—revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. Journal of Neurology. 2023;270(7):3341-3368. doi:10.1007/s00415-023-11634-0. PubMed identifier: 37022481.
- ↑ 3.0 3.1 3.2 3.3 Ginsberg DA, Boone TB, Cameron AP, et al. The American Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Diagnosis and Evaluation. The Journal of Urology. 2021;206(5):1097-1105. doi:10.1097/JU.0000000000002235. PubMed identifier: 34495687.
- ↑ 4.0 4.1 4.2 Panicker JN, Fanciulli A, Krbot Skoric M, et al. European Academy of Neurology/European Federation of Autonomic Societies/International Neuro-Urology Society Guidelines for Practising Neurologists on the Assessment and Treatment of Neurogenic Urinary and Sexual Symptoms (NEUROGED Guidelines). European Journal of Neurology. 2025;32(4):e70119. doi:10.1111/ene.70119. PubMed identifier: 40208234.